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ABSTRACT
Neglected tropical diseases (NTDs) remain a significant 
cause of morbidity and mortality in many low- income 
and middle- income countries. Several NTDs, namely 
lymphatic filariasis, onchocerciasis, schistosomiasis, 
soil- transmitted helminthiases (STH) and trachoma, are 
predominantly controlled by preventive chemotherapy (or 
mass drug administration), following recommendations 
set by the WHO. Over one billion people are now treated 
for NTDs with this strategy per year. However, further 
investment and increased domestic healthcare spending 
are urgently needed to continue these programmes. 
Consequently, it is vital that the cost- effectiveness of 
preventive chemotherapy is understood. We analyse the 
current estimates on the cost per disability- adjusted life 
year (DALY) of the preventive chemotherapy strategies 
predominantly used for these diseases and identify 
key evidence gaps that require further research. 
Overall, the reported estimates show that preventive 
chemotherapy is generally cost- effective, supporting WHO 
recommendations. More specifically, the cost per DALY 
averted estimates relating to community- wide preventive 
chemotherapy for lymphatic filariasis and onchocerciasis 
were particularly favourable when compared with other 
public health interventions. Cost per DALY averted 
estimates of school- based preventive chemotherapy for 
schistosomiasis and STH were also generally favourable 
but more variable. Notably, the broader socioeconomic 
benefits are likely not being fully captured by the DALYs 
averted metric. No estimates of cost per DALY averted 
relating to community- wide mass antibiotic treatment for 
trachoma were found, highlighting the need for further 
research. These findings are important for informing global 
health policy and support the need for continuing NTD 
control and elimination efforts.
INTRODUCTION
The neglected tropical diseases (NTDs) are 
a diverse group of conditions that are most 
prevalent in populations living in poverty.1 
Several of the most prevalent NTDs, namely 
lymphatic filariasis, onchocerciasis, schistoso-
miasis, soil- transmitted helminthiases (STH) 
and trachoma, are controlled at least in part 
by preventive chemotherapy (also referred 
to as mass drug administration)2: the large- 
scale distribution of medicines to eligible 
populations within an endemic area, without 
diagnosing or testing individual participants 
for current infection.3 Some treatment 
programmes specifically target school- aged 
children (SAC), whereas others target the 
whole community.3 Within WHO guidelines, 
different preventive chemotherapy strategies 
may be recommended depending on preva-
lence of infection for these NTDs. Generally, 
there is a minimum prevalence below which 
mass treatment is not recommended.3
When first used, preventive chemotherapy 
was often performed by mobile teams of paid 
health workers.4 However, in the mid- 1990s, 
onchocerciasis programmes shifted to using 
community- directed distributors.4–6 Later 
other NTD programmes also started using 
Summary box
 ► Several of the most prevalent neglected tropical 
diseases (NTDs), namely lymphatic filariasis, on-
chocerciasis, schistosomiasis, soil- transmitted hel-
minthiases and trachoma, are controlled at least 
in part by preventive chemotherapy (or mass drug 
administration).
 ► Many studies have found preventive chemotherapy 
to be a cost- effective strategy for controlling these 
NTDs.
 ► These findings have important implications for advo-
cacy groups and potential funders and will be useful 
for decision- makers in endemic countries to justify 
the increased domestic healthcare spending needed 
for NTD programmes.
 ► Further work is needed to inform preventive chemo-
therapy programmes and the economics of elimina-
tion programmes, particularly for trachoma where no 
relevant estimates were found.
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community volunteers, and school- based preventive 
chemotherapy programmes incorporated teachers and 
other school officials as part of the NTD workforce.3–9 
This resulted in a notable reduction in delivery costs 
and an increase in programmatic feasibility, allowing 
preventive chemotherapy programmes to expand. Over 
the last 20 years, the coverage of preventive chemo-
therapy has increased significantly (figure 1), supported 
by generous drug donations from the pharmaceutical 
industry (table 1).10 11 In 2019 alone, 1.63 billion preven-
tive chemotherapy treatments were delivered for NTDs 
worldwide.12
These NTDs cause a significant health burden, partic-
ularly among the world’s poorest and most marginalised 
in low- income and middle- income countries.1 13 de Vlas 
et al14 estimated that if the 2020 goals were achieved for 
these five NTDs, 328 million disability- adjusted life years 
(DALYs) would be averted between 2011 and 2030. In 
addition to their health impact as measured by DALYs, 
these diseases cause a significant social and economic 
burden which can exacerbate the cycle of poverty forming 
an obstacle to sustainable development.15 16
WHO and its partners have published a 2021–2030 
road map for NTDs11 (table 1) which lays out a pathway 
to sustain the gains and accelerate progress towards the 
control and elimination of these diseases. Further inte-
gration of NTD programmes into local health systems 
and greater country ownership, including a shift towards 
increased domestic healthcare spending, will likely be 
required,17–19 and has been set out within the road map 
as one of three strategic shifts for the coming decade. As 
the road map calls for country- led, evidence- based plan-
ning, there is a need for generation and use of relevant 
cost and cost- effectiveness data. It is therefore vital that 
there is a wider understanding of the evidence on the 
cost- effectiveness of preventive chemotherapy. This will 
inform future policy decisions and facilitate ongoing 
provision of resources for programmes.
This paper provides an evaluation of the existing 
evidence on the cost- effectiveness of the predominantly 
implemented preventive chemotherapy strategies for 
lymphatic filariasis, onchocerciasis, schistosomiasis, 
STH and trachoma. In addition, we highlight areas that 
require further research.
CURRENT COST-EFFECTIVENESS ESTIMATES
Cost- effectiveness analyses compare the costs and health 
effects of an intervention. The morbidities related to 
these NTDs are complex; infection can lead to different 
sequelae. Consequently, a variety of different effective-
ness metrics have been generated by cost- effectiveness 
analyses of interventions against these NTDs, including 
infections averted, disease cases or types of morbidity 
averted, heavy infections averted and DALYs averted.20–23
DALYs are a measure of disease burden and are calcu-
lated as the sum of the years of life lost due to prema-
ture mortality and the years of healthy life lost due to 
disability.24 One DALY can be interpreted as 1 year of 
‘healthy’ life lost.
DALYs averted are a more standardised and compre-
hensive effectiveness metric than disease cases averted 
and allow cost- effectiveness estimates to be directly 
compared between diseases. They are typically the 
preferred effectiveness metric for interventions in low and 
lower- middle income countries. Therefore, published 
Figure 1 Summary of global preventive chemotherapy for lymphatic filariasis, onchocerciasis, schistosomiasis, soil- 
transmitted helminthiases and trachoma from 2011 to 2019. Data adapted from the WHO NTD progress dashboard.100 Global 
coverage is based on the proportion of the population requiring treatment that is treated.
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literature reporting a cost per DALY averted are the focus 
of our analysis and we report the estimates related to the 
preventive chemotherapy strategies predominantly used 
for these diseases (see box 1). These were assumed to 
be annual community- wide treatment for lymphatic fila-
riasis, onchocerciasis and trachoma, annual school- based 
treatment for schistosomiasis and annual or biannual 
school- based treatment for STH (box 1). Further infor-
mation regarding cost- effectiveness studies and other 
economic evaluations relating to these NTDs can be 
found in previously published reviews.20–23 Information 
on how the literature was identified is provided in box 1.
It is important to note that we have focused on cost- 
effectiveness estimates reporting cost per DALY averted 
relating to the predominantly used preventive chemo-
therapy strategies for each disease (box 1). However, for 
some diseases other strategies are also performed (such 
as treatment of adults for schistosomiasis and treatment 
of pre- SAC for STH). Estimates also exist relating to alter-
native strategies, as well as other types of health economic 
assessments,20–23 25 including studies estimating economic 
and educational benefits.26
How the effectiveness of preventive chemotherapy was 
quantified
Several methodological factors can influence the effec-
tiveness estimates of preventive chemotherapy, such as 
the time horizon, the setting under investigation, the 
modelling approach and the DALY calculation. These 
need to be considered when comparing different studies 
(table 2).
Table 1 2030 goals and drug donations for lymphatic filariasis, onchocerciasis, schistosomiasis, soil- transmitted 
helminthiases and trachoma
Disease WHO 2030 goal11
Coverage 
achieved in 
201912 Drug donor and donation11
Lymphatic filariasis 
(elephantiasis)
Elimination as a public health problem 
(infection sustained below transmission 
assessment survey thresholds for at 
least 4 years after stopping mass drug 
administration; availability of essential 
package of care in all areas of known 
patients) validated in 58 (81%) countries
62.7% Eisai: up to 400 million diethylcarbamazine 
(DEC) tablets per year until elimination
Merck Sharp & Dohme: unlimited ivermectin 
in settings co- endemic with onchocerciasis 
(recently expanded to include up to 
250 million tablets per year through 2025 for 
communities eligible for the triple- therapy 
mass drug administration regimen of 
ivermectin, DEC and albendazole)
GlaxoSmithKline: up to 600 million 
albendazole tablets annually until elimination
Onchocerciasis (river 
blindness)
Elimination of transmission verified in 12 
(31%) countries




Elimination as a public health problem 
(currently defined as <1% proportion of heavy 




Merck KGaA: up to 250 million praziquantel 




Elimination as a public health problem 
(<2% proportion of soil- transmitted 
helminth infections of moderate and heavy 
intensity due to Ascaris lumbricoides, 
Trichuris trichiura, Necator americanus and 




Johnson & Johnson: 200 million mebendazole 
tablets annually for SAC until 2025
GlaxoSmithKline: 200 million albendazole 
tablets annually for SAC
Trachoma Elimination as a public health problem ((i) 
a prevalence of trachomatous trichiasis 
‘unknown to the health system’ of <0.2% 
in ≥15- year- olds in each formerly endemic 
district; (ii) a prevalence of trachomatous 
inflammation—follicular in children aged 
1–9 years of <5% in each formerly endemic 
district; and (iii) written evidence that the 
health system is able to identify and manage 
incident cases of trachomatous trichiasis, 
using defined strategies, with evidence of 
appropriate financial resources to implement 
those strategies) validated in 64 (100%) 
countries
57.2% Pfizer: unlimited quantity of azithromycin until 
2025
Pre- SAC, Pre- school- age children; SAC, School- age children.  on S
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A key consideration is the time horizon of the analyses 
which determines the duration over which outcomes and 
costs are calculated (table 2). If the time horizon is too 
short, the long- term benefits of preventive chemotherapy 
may not be accounted for, underestimating its cost- 
effectiveness. As time horizons vary between studies, this 
parameter is likely a key driver of variability among the 
estimates. Importantly, many of the studies had time hori-
zons under 10 years and therefore did not fully capture 
longer- term costs and benefits associated with achieving 
NTD control or elimination (table 2).
A further important consideration when comparing 
different studies is the geographical and epidemiolog-
ical setting being investigated. Some studies focused 
on a specific area whereas others focused on a whole 
regional or global programme. The baseline prevalence 
of infection varied across studies. This impacted effec-
tiveness estimates, because in general, the higher the 
baseline prevalence, the greater the health impact of 
preventive chemotherapy and therefore the greater the 
cost- effectiveness (table 2). Most studies investigated the 
effect of preventive chemotherapy on one NTD, though 
a few studies considered the effect on two NTDs and one 
study considered the simultaneous effect on three NTDs 
(table 2).
Various approaches have been used in cost- 
effectiveness studies to quantify the impact of preven-
tive chemotherapy, ranging from back- of- the- envelope 
calculations to dynamic transmission models (table 2). 
Dynamic transmission models are often used to estimate 
the population- level effectiveness of preventive chemo-
therapy as such models can account for the intervention’s 
indirect benefits on those not treated and the density- 
dependent processes which govern infection transmis-
sion.25 Static models do not account for these processes 
and therefore may not capture the full benefits of preven-
tive chemotherapy.
DALY calculations are highly sensitive to changes in 
assigned disability weights and which sequelae of infec-
tion are included. Notably, the disability weights used for 
NTDs have changed significantly since Global Burden of 
Disease Study (GBD) 201027 28 (see online supplemental 
Table S1) for the disability weights used by the GBD 2019 
for these NTDs). For example, the disability weight for 
blindness decreased (somewhat controversially) from 
0.60 to 0.19.29 30 This is an important source of variation 
in cost- effectiveness estimates and needs to be consid-
ered when interpreting available data. DALY calculations 
for schistosomiasis and STH have been a source of debate 
and various approaches have been taken in different 
studies.23 31–36 For example, cognitive impairment was 
removed as a quantifiable sequela of STH infection for 
GBD 2010. Although this was justified by a perceived lack 
of evidence of causation,37 it is an area of debate within 
the field.38 39 It may be difficult to reach a definitive 
conclusion regarding the impact of STH on cognition 
and this should be acknowledged when interpreting cost- 
effectiveness analyses. Due to the uncertainties associated 
with the DALY calculations for NTDs, a degree of caution 
should be employed when interpreting cost- effectiveness 
estimates, particularly for targeting schistosomiasis and 
STH in different age groups or in areas of low prevalence 
and intensity of infection.40
It is important to consider that the framework for 
estimating DALYs does not necessarily fully summarise 
the disease burden of these NTDs. As examples, 
onchocerciasis- associated epilepsy41 42 is not fully 
accounted for, the potential mental health burden for 
some of the sequelae is not always considered43 44 and 
(due in part to lack of data) potential excess mortality 
conferred by these diseases is not always included. This 
could lead to the health impacts being underestimated. 
Additionally, we recognise that the DALY framework 
fails to acknowledge the implications of context on the 
burden of disease, with those living in poverty or with 
poor access to healthcare typically affected far more than 
people in higher socioeconomic strata or than those with 
access to affordable healthcare.45
Box 1 Selection criteria
The focus of this analysis was on published estimates reporting a 
cost per disability- adjusted life year (DALY) averted. We summarised 
the estimates from published literature reporting average cost- 
effectiveness ratios related to cost per DALY averted for the 
predominantly used preventive chemotherapy strategies relative to 
a do- nothing comparator. The predominantly used strategies were 
assumed to be annual community- wide treatment for lymphatic 
filariasis, onchocerciasis and trachoma, annual school- based 
treatment for schistosomiasis and annual or biannual school- 
based treatment for soil- transmitted helminthiases (STH). This was 
informed by the WHO Preventive Chemotherapy and Transmission 
Control databank (note that for some diseases these are not the only 
strategies used).101 We included estimates related to stand- alone 
preventive chemotherapy and excluded those in which preventive 
chemotherapy was combined with additional interventions, such as 
antibiotic mass drug administration and surgery for trachoma. No time 
restrictions were made regarding which estimates were included. 
Cost- effectiveness estimates relating to alternative strategies (as 
well as incremental cost- effectiveness ratios of scaling up preventive 
chemotherapy programmes) and estimates relating to treatment in 
areas below the currently recommended prevalence cut- offs for mass 
treatment were excluded.3 Studies reporting metrics other than a cost 
per DALY averted were excluded.
We identified the relevant studies from previously published 
disease- specific systematic reviews20–23 and also carried out an 
updated search for more recent data published in the peer- reviewed 
press. For trachoma, no previously published systematic review was 
available and therefore the studies were only identified via the search. 
Updated searches were of MEDLINE, PubMed and in the reference 
lists from relevant published articles found within those searches. 
We used combinations of the search terms ‘lymphatic filariasis’, 
‘onchocerciasis’, ‘schistosomiasis’, ‘soil- transmitted helminthiases 
(STH)’, ‘ascaris’, ‘trichuris’, ‘hookworm’, ‘trachoma’, ‘cost- 
effectiveness’, ‘cost- utility’, ‘cost per DALY averted’. No language or 
date restrictions were used. Note: although searches were conducted, 
this is not a formal systematic review.
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How costs of preventive chemotherapy were quantified
The way in which costs are quantified will impact the 
estimates of the cost- effectiveness of preventive chemo-
therapy. The methods used to parameterise the costs 
differed widely across studies: some were based on 
primary data whereas others used assumed crude bench-
marks. The delivery costs were generally assumed to be 
around US$0.50 per treatment (table 2), consistent with 
current benchmarks.46 However, delivery costs vary across 
different settings with the size of the target population 
being a key driver in this variation.20–23 46–50 This is because 
delivery costs for preventive chemotherapy tend to show 
economies of scale that is, as the number of people 
treated increases, the cost per treatment decreases.47 51
It should be noted when looking at the assumed costs 
that the annual costs of preventive chemotherapy also 
change depending on the distribution method. The 
least costly and resource intensive strategy is likely to 
be incorporating the distribution into an established 
health system platform/existing programme (such as a 
Child Health Day), followed by school- based treatment 
and then community- wide treatment.21 52 In addition, the 
costs are influenced by how the strategy is implemented. 
For example, the use of volunteer community distrib-
utors or teachers would be cheaper than paid health 
workers.21 53
When looking at these studies, it is important to 
consider whether they are using financial or economic 
costs (table 2). Financial costs represent the amount paid 
for the goods, resources and services that are purchased. 
Economic costs conceptualise costs more broadly and 
represent the full value of the resources used for an inter-
vention, including the value of donated resources, such 
as the unpaid time of community health volunteers.53 It 
is typically recommended to use economic costs within 
economic evaluations.54 55 Not all studies clearly reported 
the type of cost data used or their source (table 2).
As drugs used for these NTDs are typically donated 
(table 1), they are often not counted as a financial cost 
for the health ministry within preventive chemotherapy 
programmes. Their value can, however, be included as 
an economic cost, depending on the viewpoint from 
which the intervention’s costs and consequences are eval-
uated (ie, the study’s perspective). The value of donated 
medicines can be a significant cost. For example, it has 
been estimated that the value of pharmaceutical part-
ners’ donated products for the 10 NTDs included in the 
London Declaration was US$2–3 billion annually.56 In 
practice, it is difficult to estimate the true economic cost 
of drugs that are donated for preventive chemotherapy 
programmes, as the assumed costs/value of these drugs 
varies and the correct value to use is debatable.20–23 57 58 If 
and how the donated drugs are valued are sources of vari-
ation in cost- effectiveness estimates of preventive chemo-
therapy, particularly for ivermectin and azithromycin as 
the economic values reported by the companies donating 
them are higher than those for other donated drugs. 
Such variation needs to be considered when interpreting 
the results from older costing and cost- effectiveness 
studies. Furthermore, when a commitment has been 
made to donate a drug for as long as needed (table 1), 
it is debatable whether its economic value should be 
included within economic evaluations.
Estimates of the cost per DALY averted
Table 2 and box 2 summarise the key cost- effectiveness 
estimates in terms of DALYs averted relating to the 
predominantly used preventive chemotherapy strategies. 
These estimates generally represent the overall mean 
cost- effectiveness of a NTD preventive chemotherapy 
programme, or its cost- effectiveness in one specific 
setting. Importantly, most of the estimates relate to one 
disease. However, a study by De Neve et al59 investigated 
the cost- effectiveness of school- based preventive chemo-
therapy for multiple diseases (lymphatic filariasis, schis-
tosomiasis and STH), highlighting that the overall cost- 
effectiveness of preventive chemotherapy depends on 
how many NTDs treated by the distributed medicines 
are co- endemic in the location under consideration. 
Notably, none of the estimates considered the impact of 
the preventive chemotherapy on non- targeted diseases.
Overall, the cost- effectiveness estimates of preventive 
chemotherapy against lymphatic filariasis and onchocer-
ciasis that we identified (US$3–133 per DALY averted; 
table 2) were favourable compared with the main cost- 
effectiveness thresholds used for low- income countries 
(outlined in box 3) and compared with other interven-
tions conducted in low- income and middle- income coun-
tries, with estimates on par with those associated with 
interventions for other major global health problems. For 
example, supplying insecticide- treated nets for malaria 
has been estimated to cost US$61–94 per DALY averted 
in three African settings (2012 prices).60–62 A compre-
hensive list of cost- effectiveness estimates for a range of 
public health interventions is provided by Horton et al.63
The estimated cost- effectiveness of preventive chemo-
therapy for schistosomiasis and STH was also generally 
favourable (US$8–1077 per DALY averted; table 2) but 
more variable than estimates for lymphatic filariasis 
and onchocerciasis. For schistosomiasis and STH, the 
estimated cost per DALY averted was generally found 
to be below a cost- effectiveness threshold less than half 
the country’s per capita GDP,64 65 with some more prom-
ising estimates below the disease control priorities (third 
edition) US$200 per DALY averted threshold.66 Here, 
the highest estimate of US$1077 falls above these conser-
vative thresholds (Box 3) but this is related to a 20% STH 
prevalence setting below which preventive chemotherapy 
is not recommended. In addition to the prevalence 
setting, variation in these estimates is likely to be partly 
driven by the methods used to calculate corresponding 
DALY burdens and how they are changing over time. 
It is debatable whether the number of DALYs averted 
(which focus on health) are truly capturing all long- term 
benefits of treating schistosomiasis and STH. Hicks et al67 
recently demonstrated significant long- term economic 
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benefits of deworming children, for example, on house-
hold income, and its potential social rate of return.
We identified no published estimates of cost per DALY 
averted relating to community- wide mass treatment for 
trachoma. Available cost- effectiveness estimates exam-
ined the cost of targeting children only (online supple-
mental Table S2 and box 1); the currently used strategy 
is community- wide mass treatment.68 Effectiveness trials 
comparing community- wide treatment to treatment 
of children only have been conducted69 but have not 
changed global policy. Further health economics anal-
yses are needed before more definitive conclusions can 
be drawn.
Implications of these cost-effectiveness estimates
Overall, the reported estimates show that the predom-
inantly used preventive chemotherapy strategies are 
generally cost- effective, thereby supporting WHO recom-
mendations. The generalisability of these estimates 
depends on multiple factors, including the epidemiolog-
ical setting and drivers that influence the delivery costs, 
Box 2 Summary of the cost per disability- adjusted life 
year (DALY) averted estimates
Lymphatic filariasis: Turner et al57 estimated that the cost per DALY 
averted for preventive chemotherapy delivered within the Global 
Programme to Eliminate Lymphatic Filariasis was US$24 when using 
financial costs, US$29 when using economic costs excluding the value 
of the donated drugs and US$64 when using economic costs including 
the value of the donated drugs (2014 prices). Analysis within the 
second edition of the disease control priorities in developing countries 
(DCP2)102 estimated that lymphatic filariasis related preventive 
chemotherapy costs approximately US$29 per DALY averted within 
a control scenario and between US$4.40–8.10 per DALY averted (*) 
within two elimination scenarios.
Onchocerciasis: Based on dynamic transmission modelling and 
assuming and economic delivery cost of US$0.52 per treatment, 
Turner et al104 estimated that long- term preventive chemotherapy 
in an African savannah setting cost between US$3–15 per DALY 
averted (2012 prices) depending on the assumed endemicity level 
and excluding the value of the donated drugs. The results changed 
to US$29–133 per DALY averted (2012 prices) when including the 
additional economic value of the donated ivermectin.104 Coffeng et 
al103 estimated based on the simulated benefits and reported financial 
costs of the African Programme for Onchocerciasis Control occurring 
between 1995–2015, a cost of US$27 per DALY averted (nominal 
values). Analysis within the DCP2102 estimated that onchocerciasis 
related preventive chemotherapy costs approximately US$7 per DALY 
averted (*).
Schistosomiasis: Lo et al31 estimated the cost- effectiveness 
of school- based preventive chemotherapy in four communities 
in Côte d’Ivoire, resulting in an average cost per DALY averted of 
US$118 (2014 prices). Most (92%) of the disability resulted from 
Schistosoma infections. Miguel and Kremer108 estimated that within 
their study of school- based preventive chemotherapy in Kenya, 
it cost US$5 per DALY averted (*) with 99% of the benefit due to 
averted schistosomiasis. Analysis within the DCP27 estimated 
that treating school- aged children (SAC) for schistosomiasis costs 
US$336–692 per DALY averted (*) (note that this is incorrectly quoted 
as US$3.36–6.92 within the published report).105 GiveWell estimated 
that school- based preventive chemotherapy for schistosomiasis cost 
US$28.19–70.48 per DALY averted (*).106 Lo et al32 also showed that 
the cost- effectiveness of school- based preventive chemotherapy 
against schistosomiasis was highly influenced by the local prevalence 
of infection—15% prevalence: US$449 per DALY averted, and 30% 
prevalence: US$160 per DALY averted (2015 prices). Community- wide 
preventive chemotherapy tended not to be more cost- effective,23 31 32 
that is, it did not have a lower cost per DALY averted. However, it 
could be classed as cost- effective depending on the chosen cost- 
effectiveness threshold.
Soil- transmitted helminthiases (STH): Chan107 estimated that 
treating SAC for Ascaris lumbricoides is highly cost- effective in a high 
prevalence community; US$8 per DALY averted (cost year not stated). 
Analysis within the DCP27 estimated that treating SAC for STH costs 
US$326 per DALY averted (note that within the report the results were 
reported as US$3.41 per DALY averted (*), but there were errors within 
the calculation).105 GiveWell re- estimated the cost- effectiveness 
(using a different methodology) and obtained an estimate of US$83 
per DALY averted (*).105 106 Miguel and Kremer108 estimated that within 
their study the cost per STH- related DALY averted would be US$280 
(*). Lo et al32 also showed that the cost- effectiveness of school- based 
preventive chemotherapy against STH was highly influenced by the 
Continued
Box 2 Continued
prevalence of infection—20% prevalence: US$1077 per DALY averted, 
60% prevalence: US$298 per DALY averted, 85% prevalence: US$174 
per DALY averted (2015 prices).
Trachoma: We identified no published cost per DALY averted 
estimates relating to the currently used strategy of community- wide 
mass treatment for trachoma using single- dose oral azithromycin. 
This is now the antibiotic of choice.111 In terms of other studies, 
the Myanmar trachoma control programme was estimated in 1996 
by Evans et al112 to have required, over the course of 30 years 
implementation, only US$11 for non- surgical interventions (mass 
treatment with topical antibiotics and community education) for 
each handicap- adjusted life- year saved. In 2005, Baltussen et al113 
estimated that targeted mass antibiotic treatment of children for 
trachoma control purposes cost between I$9012–65 022 per DALY 
averted. (International dollars (I$) are a hypothetical currency unit 
designed to capture the differences in relative prices across different 
settings). These estimates included the contemporary market price of 
azithromycin and its assumed price had a large impact on the results. 
In practice, virtually all azithromycin used by trachoma programmes 
is now donated by the manufacturer. When antibiotics are assumed 
to have no cost to the healthcare system (reflecting donated drugs) 
or to have been purchased at using generic prices obtainable in India 
(which are 16 times cheaper), the cost- effectiveness improved, but 
cost per DALY averted remained relatively high compared with that for 
other neglected tropical diseases (online supplemental Table S2). In 
a two- world- region update of the 2005 paper113 (again including the 
cost of azithromycin), Baltussen et al,114 concluded that targeted mass 
antibiotic treatment of children with azithromycin to control trachoma 
could be considered cost- effective in the African Region (I$2101 per 
DALY averted) but not the South East Asia Region (I$8051 per DALY 
averted).114 Critiques of these analyses have been published.115 116 
Further analyses are needed before definitive conclusions can be 
drawn.
Note that it was not possible to adjust the different studies for inflation.
*; cost year not clearly stated.
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such as remoteness and implementation methods. In 
terms of epidemiological settings, the estimated health 
benefits and cost- effectiveness of preventive chemo-
therapy are generally greater for higher transmission 
settings. Furthermore, the use of volunteer community 
distributors could have either positive or negative influ-
ences on programmatic outcomes depending on the 
setting.70 Hence, it is important to consider these factors 
when comparing and interpreting different studies for 
informing policy decisions.
Although the estimates are encouraging, as the 
financing of NTD programmes shifts towards a greater 
contribution from endemic countries, it is important 
that policymakers consider the cost- effectiveness of these 
interventions relative to other diseases/priorities in their 
setting. Budget impact analyses may also be required to 
identify packages that are too expensive.
In terms of priority setting and policy decisions beyond 
the cost per DALY averted, it is also important to consider 
the broader socioeconomic benefits of these NTD 
programmes.15 For example, Redekop et al16 estimated 
notable social economic benefits would occur from 
achieving the 2020 targets for these five diseases, both 
in terms of averted out- of- pocket health expenditure and 
averted productivity losses (totalling US$229.5 (162.3–
344.8) billion in the period 2011–2030 (2015 prices)). 
Ahuja et al26 provide a comprehensive summary of the 
social- economic benefits of deworming. This highlights 
the broader value of investment in these programmes, 
particularly in the context of universal health coverage, 
social protection and reducing inequalities, which are 
not captured fully by the DALYs averted metric.15
FUTURE RESEARCH NEEDS
Over the last decade, there has been a notable increase 
in the number of thorough economic evaluations of 
preventive chemotherapy, increasing the evidence base 
for this intervention. However, there are many areas in 
which further research would help to inform policy.
Estimating the health benefits of preventive chemotherapy
The current framework for estimating DALYs does not 
necessarily fully summarise the disease burden of these 
NTDs, potentially underestimating the cost- effectiveness 
of interventions against them. Further research is needed 
to comprehensively capture the health benefits of preven-
tive chemotherapy. For example, how to better estimate 
the health impacts of preventive chemotherapy (particu-
larly when targeting different age groups) is especially 
important for schistosomiasis and STH, as well as how to 
quantify the excess mortality associated with these NTDs. 
In addition, the potential disease burden associated 
with mental health issues (such as depression) related 
to these NTDs is not always currently quantified in the 
standard DALY calculations for some NTD sequelae. 
Further investigation is needed of the causal relation-
ship between infection and mental health outcomes and 
their prevalence—not only for the patients but also their 
caregivers.43 71
In future studies, there is a vital need for greater trans-
parency on how numbers of DALYs averted are esti-
mated, particularly with respect to disability weights and 
their source. Any changes from the approach used within 
the most recent GBD study needs to be clearly stated and 
justified.
Cost- effectiveness analyses published to date have 
typically investigated the impact of preventive chemo-
therapy on one NTD (table 2). However, preventive 
chemotherapy for NTDs uses relatively broad- spectrum 
drugs that can also have an impact on other co- en-
demic infections,72–77 or even on all- cause morbidity and 
mortality.78–80 For example, mass ivermectin distribution 
will also have an impact on strongyloidiasis, scabies, ecto-
parasites and mosquito mortality.73 75 81–84 Consequently, 
the overall cost- effectiveness of preventive chemotherapy 
is likely to be underestimated. Further quantification of 
these auxiliary benefits is needed.
Beyond this, it is important that further research is 
conducted on the broader non- health- related benefits 
of preventive chemotherapy, including socioeconomic 
benefits such as educational and occupational outcomes, 
productivity gains, and financial protection.
Integrated NTD control
As NTD programmes push towards greater integration 
(whereby multiple disease- specific programmes are 
delivered within a single programme or local health 
system) and expand their footprint towards the provision 
Box 3 Cost- effectiveness thresholds
To determine whether an intervention is cost- effective, the cost 
per disability- adjusted life year (DALY) averted is often compared 
with a cost- effectiveness (willingness to pay) threshold. The most 
appropriate cost- effectiveness thresholds to use within global health 
are under debate.117–119 When no country- specific threshold has been 
set, some studies used the cost- effectiveness thresholds set by the 
Commission on Macroeconomics and Health120; namely a cost per 
DALY averted <3 or <1 times the country’s gross domestic product 
(GDP) per capita for an intervention to be considered cost- effective or 
highly cost- effective, respectively. As a benchmark, using the mean 
GDP for low- income countries in 2019, these thresholds would be 
US$2430 and US$810, respectively.121 However, these thresholds are 
now considered too high and have been widely criticised.65 117–119 122 
The WHO has emphasised that these thresholds were not intended for 
individual country level- investment decisions but as a broad principle 
for global or regional consideration. Recent analyses have indicated 
that a cost- effectiveness threshold of <0.5 times the country’s GDP 
per capita would be more appropriate for low- income countries64 65; 
corresponding to US$405 based on the average GDP for low- income 
countries in 2019.121 For comparison, the third edition of the Disease 
Control Priorities project used a threshold of US$200 per DALY averted 
to identify priority interventions for consideration in low- income 
countries.66 It is vital that conclusions of economic evaluations are 
re- interpreted in light of such changes: it is likely that some previous 
conclusions regarding the interventions or strategies that should be 
rated cost- effective will no longer hold.
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of universal health coverage, it would be useful for 
decision- makers to be able to consider cost- effectiveness 
of integrated NTD control programme packages, rather 
than stand- alone disease- specific interventions.17–19 A 
better understanding of the costs of integrated control 
programmes85 86 and how integration may influence the 
costs and cost- effectiveness of implementing different 
control strategies will be required for this.
Further economic evaluations on areas where NTDs 
are co- endemic are important as a study by Lo et al32 high-
lighted that the optimal strategy for schistosomiasis and 
STH can depend on whether they are co- endemic.
Economic evaluations of alternative preventative 
chemotherapy strategies and complementary interventions
A key research area for these NTDs is where and when 
alternative preventive chemotherapy strategies should be 
used, such as increasing treatment frequency, targeting 
different age groups or using a different drug or drug 
combination. There is a need for more data on the rela-
tive costs of different preventive chemotherapy strat-
egies in different settings. For example, there are few 
primary data on the relative cost of school- based versus 
community- wide preventive chemotherapy.21 Concern-
ingly, many economic evaluations on this topic make 
assumptions regarding the relative cost of these strategies 
based on limited data. This is a research gap that needs to 
be addressed to inform policy. Due to economies of scale 
and variation in delivery costs between areas, it is usually 
not possible to generalise cost data from different studies 
for this purpose.47
The potential for leveraging existing delivery platforms, 
such as child health days or antenatal clinics, could be 
considered more often when evaluating possible preven-
tive chemotherapy strategies. It is likely that building on 
established health system platforms to deliver treatment 
could be cheaper than undertaking dedicated preventive 
chemotherapy.17 87 For example, Boselli et al88 estimated 
that adding deworming into an existing immunisation 
and vitamin A supplementation campaign would cost 
less than US$0.01 per deworming treatment. Further 
implementation research is needed to assess the possible 
use of such platforms,89 with potential benefits and risks 
evaluated. This may be particularly important when 
considering a shift from school- based to community- 
wide treatment for schistosomiasis and STH. If sufficient 
coverage of high- risk adults for schistosomiasis and STH 
could be achieved with established platforms, using them 
could be more cost- effective than community- wide mass 
treatment.
More economic evaluations on complementary inter-
ventions for these NTDs, such as water, sanitation and 
hygiene measures, behaviour change interventions and 
vector control are required. In addition to preventive 
strategies, it is also important to further evaluate the cost- 
effectiveness of morbidity management strategies.
Further research is required for settings where oncho-
cerciasis is co- endemic with loiasis. Individuals heavily 
infected with loiasis can experience severe and some-
times fatal neurological sequelae after ivermectin treat-
ment.90 91 Ivermectin- based mass drug administration is 
not recommended in hypo- endemic areas for onchocer-
ciasis (<40% microfilariae or <20% nodules prevalence) 
that are co- endemic for loiasis.92 Consequently, alterna-
tive preventive chemotherapy strategies are needed in 
these settings. One solution is screening every member 
of the population for loiasis before treatment, treating 
all those with no or low- intensity Loa loa infection and 
excluding those with a high- intensity infection. However, 
such a test- and- (not)- treat approach is more costly than 
standard preventive chemotherapy.93 Lymphatic filariasis 
control strategies using ivermectin are also impeded in 
settings co- endemic with loiasis and need to be adapted. 
In these areas, twice- yearly albendazole monotherapy 
in combination with coordinated vector control is the 
recommended strategy.94 This strategy will require 
additional cost due to additional rounds of treatment 
compared with multi- drug combinations. There is a need 
for further economic evaluations of the optimal alterna-
tive strategies for these settings. Importantly, these will 
need to consider not only the costs and benefits but also 
consider the programme goals as a whole and the risk of 
such settings acting as sources of re- infection to neigh-
bouring populations.
When considering the cost- effectiveness of new strat-
egies or interventions, an important consideration is 
whether the goal is disease/morbidity control or inter-
ruption of transmission.20 22 Which strategies are cost- 
effective can be influenced by the goal of the programme. 
More intensive strategies may not be cost- effective when 
the goal is controlling morbidity but could be when 
aiming for interruption of transmission.20 22 For example, 
though complementary vector control for lymphatic fila-
riasis has a notable effect on transmission,95 96 it may not 
necessarily be cost- effective for controlling morbidity (ie, 
in terms of the additional health benefits gained from 
that setting compared with preventive chemotherapy 
only) but could be cost- effective in terms of its long- 
term impact on transmission in the context of achieving 
elimination goals (such as reducing the risk of resur-
gence).20 The framework for the economic evaluation 
of elimination strategies needs further investigation and 
development. In particular, a pressing need is how we 
evaluate the cost- effectiveness of maintaining control 
versus moving towards interruption of transmission and 
the cost- effectiveness of adding complementary interven-
tions (such as a combined preventive chemotherapy and 
vector control strategy).
Contextual factors that affect the cost-effectiveness of NTD 
programmes
Current cost- effectiveness estimates generally represent 
the overall mean cost- effectiveness of a NTD preventive 
chemotherapy programme, or its cost- effectiveness in 
one specific setting. Further investigation is needed of the 
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contextual factors that affect cost- effectiveness estimates 
and their potential variation across different settings.
A key contextual factor is the delivery cost of preven-
tive chemotherapy. There is a need for further cost 
data from a wider range of settings and programmatic 
contexts.46 These delivery costs may be influenced by the 
stability and accessibility of the area (such as access to 
forest settings) and the costs associated with expanding 
treatment programmes to target harder- to- reach areas/
groups may have diseconomies of scale.47 Due to this, 
the cost per treatment of NTD control programmes will 
likely increase as end goals are approached.47
The epidemiological setting, such as the level of trans-
mission (baseline prevalence of infection), endemic NTD 
species, age profile of infected individuals and historic 
coverage, can notably influence the cost- effectiveness 
of different preventive chemotherapy strategies. For 
example, the benefits of moving from school- based to 
community- wide treatment for schistosomiasis and STH 
depends on the burden of infection in adults.21 23 40 97 The 
impact of the epidemiological setting on the generalis-
ability of studies needs further investigation, particularly 
when considering a change in strategy. If such variation 
in epidemiological settings is not properly accounted 
for there is a danger that studies will be overgeneralised 
leading to inappropriate policy decisions.
CONCLUSION
Many studies have found preventive chemotherapy to be 
a cost- effective strategy for controlling several NTDs. The 
cost per DALY averted estimates relating to community- 
wide preventive chemotherapy for lymphatic filariasis and 
onchocerciasis were particularly favourable when other 
public health interventions. The estimates for school- 
based preventive chemotherapy for schistosomiasis 
and STH were also generally favourable but more vari-
able. There were no estimates of cost per DALY averted 
relating to community- wide mass antibiotic treatment for 
trachoma. It is important to acknowledge that the DALYs 
averted metric may not be capturing the broader socioec-
onomic benefits for controlling these diseases.
Overall, these findings support the need for continuing 
NTD control and elimination efforts, providing important 
implications for advocacy groups, potential funders 
and decision- makers in endemic countries to justify the 
increased domestic healthcare spending needed for NTD 
programmes. These findings and the need for further 
work are increasingly important in light of the current 
coronavirus 2019 (COVID-19) pandemic, as there is a 
risk that there will be even more limited resources and 
financing to resume public health programmes in the 
coming years.98 99
Although these results are promising, it does not mean 
that preventive chemotherapy is a cost- effective interven-
tion in every setting where these infections are endemic. 
Hence, WHO recommendations on use of different 
strategies depending on the endemicity of these diseases 
(including, at times a minimum infection prevalence 
threshold for mass treatment) is underlined. Accordingly, 
there is no one- size- fits- all approach regarding the best 
preventive chemotherapy strategy for controlling NTDs 
as this will depend on the local setting: which NTDs are 
endemic, at what levels of transmission, and whether the 
goal is controlling morbidity or interruption of transmis-
sion. Further work including cost- effectiveness analyses is 
needed to inform preventive chemotherapy programmes 
and the economics of elimination programmes.
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